Altamira Therapeutics Ltd (CYTO)

$0.91

-0.01

(-1.09%)▲

Market is closed - opens 7 PM, 09 Sep 2024

Performance

  • $0.86
    $0.92
    $0.91
    downward going graph

    5.05%

    Downside

    Day's Volatility :6.58%

    Upside

    1.61%

    downward going graph
  • $0.16
    $17.20
    $0.91
    downward going graph

    82.91%

    Downside

    52 Weeks Volatility :99.1%

    Upside

    94.71%

    downward going graph

Returns

PeriodAltamira Therapeutics LtdIndex (Russel 2000)
3 Months
-36.36%
0.0%
6 Months
-51.6%
0.0%
1 Year
-86.72%
0.0%
3 Years
-99.91%
-22.3%

Highlights

Market Capitalization
3.0M
Book Value
$4.37
Earnings Per Share (EPS)
-17.49
Wall Street Target Price
8.24
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-52.83%
Return On Equity TTM
-964.17%
Revenue TTM
120.3K
Revenue Per Share TTM
0.92
Quarterly Revenue Growth YOY
-63.7%
Gross Profit TTM
-2.2M
EBITDA
-5.8M
Diluted Eps TTM
-17.49
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-4.61
EPS Estimate Next Year
-3.42
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Altamira Therapeutics Ltd(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 805.49%

Current $0.91
Target $8.24

Technicals Summary

Sell

Neutral

Buy

Altamira Therapeutics Ltd is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Altamira Therapeutics Ltd
Altamira Therapeutics Ltd
-3.19%
-51.6%
-86.72%
-99.91%
-99.92%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
5.97%
16.25%
37.11%
69.18%
305.56%
Novo Nordisk A/s
Novo Nordisk A/s
9.99%
-3.52%
34.24%
158.74%
417.73%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
-5.15%
64.67%
22.72%
31.08%
198.44%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
0.45%
14.0%
36.06%
143.5%
167.72%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Altamira Therapeutics Ltd
Altamira Therapeutics Ltd
NA
NA
NA
-4.61
-9.64
-0.53
NA
4.37
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
29.93
29.93
1.54
45.05
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
44.01
44.01
1.98
3.44
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.55
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.57
0.32
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Altamira Therapeutics Ltd
Altamira Therapeutics Ltd
Buy
$3.0M
-99.92%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$124.7B
305.56%
29.93
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$585.3B
417.73%
44.01
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$32.3B
198.44%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$120.9B
167.72%
32.84
-4.74%

Insights on Altamira Therapeutics Ltd

  • Increasing Revenue

    Revenue is up for the last 3 quarters, -458.69K → 52.73K (in $), with an average increase of 484.9% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -9.61M → -2.71M (in $), with an average increase of 127.3% per quarter

  • Vs REGN

    In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 37.1% return, outperforming this stock by 123.8%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 69.2% return, outperforming this stock by 169.1%

Institutional Holdings

  • Tower Research Capital LLC

    0.05%

Company Information

altamira therapeutics (former auris medical) is dedicated to developing therapeutics that address important unmet medical needs. the company is currently active in three areas: • the development of rna therapeutics for extrahepatic therapeutic targets (oligophore™ / semaphore™ platforms; preclinical), • nasal sprays for protection against airborne viruses and allergens (bentrio™; commercial) or the treatment of vertigo (am-125; phase 2) • the development of therapeutics for intratympanic treatment of tinnitus or hearing loss (keyzilen® and sonsuvi®, phase 3). the company was founded in 2003, under the name auris medical, and is headquartered in hamilton, bermuda with its main operations in basel, switzerland. the shares of altamira therapeutics ltd. trade on the nasdaq capital market under the symbol “cyto.”

Organization
Altamira Therapeutics Ltd
Employees
10
CEO
Dr. Thomas Meyer Ph.D.
Industry
Miscellaneous

Discover More

FAQs